Key issues in the management of patients with systemic lupus erythematosus: Latest developments and clinical implications

Therapeutic Advances in Musculoskeletal Disease

Volumn 7, Issue 6, 2015, Pages 234-246

  Jordan, Natasha ^a   D'cruz, David ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

biologic therapies; long term damage accrual; treat to target

Indexed keywords

ABATACEPT; ANIFROLUMAB; APRIL PROTEIN; ATACICEPT; B CELL ACTIVATING FACTOR; BELIMUMAB; BORTEZOMIB; EPRATUZUMAB; RITUXIMAB; RONTALIZUMAB; SIFALIMUMAB; SIRUKUMAB; TABALUMAB; TOCILIZUMAB;

B LYMPHOCYTE; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

EID: 84946018186     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X15601805     Document Type: Review

References (92)

1. Adler S. Kolev M. Varisco P. Tham M. von Gunten M. Tappeiner C. et al (2013) Induction of severe systemic lupus erythematosus by TNF blockade and response to anti-IL-6 strategy. J Allergy Clin Immunol 131: 1235–1237, 1237 e1231.
2. Alexander T. Sarfert R. Klotsche J. Kühl A. Rubbert-Roth A. Lorenz H. et al (2015) The proteasome inhibitor bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 74: 1474–1478.
3. Baechler E. Batliwalla F. Karypis G. Gaffney P. Ortmann W. Espe K. et al (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 100: 2610–2615.
4. Bengtsson A. Sturfelt G. Truedsson L. Blomberg J. Alm G. Vallin H. et al (2000) Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 9: 664–671.
5. Bennett L. Palucka A. Arce E. Cantrell V. Borvak J. Banchereau J. et al (2003) Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197: 711–723.
6. Bernatsky S. Boivin J. Joseph L. Manzi S. Ginzler E. Gladman D. et al (2006) Mortality in systemic lupus erythematosus. Arthritis Rheum 54: 2550–2557.
7. Bruce I. O'Keeffe A. Farewell V. Hanly J. Manzi S. Su L. Gladman D. et al (2014) Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 16 May 2014. [Epub ahead of print]
8. Brunet J. Denizot F. Luciani M. Roux-Dosseto M. Suzan M. Mattei M. et al (1987) A new member of the immunoglobulin superfamily-CTLA-4. Nature 328: 267–270.
9. Burton M. Winthrop K. Baddley J. (2015) Hepatitis reaction with rituximab sparks drug safety alert. The Rheumatologist, press release, 1 January 2015.
10. Calabrese L. Molloy E. (2008) Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 67: 64–65.
11. Cambridge G. Isenberg D. Edwards J. Leandro M. Migone T. Teodorescu M. et al (2008) B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 67: 1011–1016.
12. Catapano F. Chaudhry A. Jones R. Smith K. Jayne D. (2010) Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant 25: 3586–3592.
13. Cheema G. Roschke V. Hilbert D. Stohl W. (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44: 1313–1319.
14. Chun H. Chung J. Kim H. Yun J. Jeon J. Ye Y. et al (2007) Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 27: 461–466.
15. Cohen S. Emery P. Greenwald M. Dougados M. Furie R. Genovese M. et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54: 2793–2806.
16. Collins C. Gavin A. Migone T. Hilbert D. Nemazee D. Stohl W. (2006) B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 8: R6.
17. Condon M. Ashby D. Pepper R. Cook H. Levy J. Griffith M. et al (2013) Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72: 1280–1286.
18. Cunnane G. Chan O. Cassafer G. Brindis S. Kaufman E. Yen T. et al (2004) Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide. Arthritis Rheum 50: 1539–1548.
19. Daikh D. Wofsy D. (2001) Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 166: 2913–2916.
20. Dall'era M. Chakravarty E. Wallace D. Genovese M. Weisman M. Kavanaugh A. et al (2007) Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 56: 4142–4150.
21. Danila M. Pons-Estel G. Zhang J. Danila M. Zhang J. Bastian H. et al (2009) Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology 48: 542–545.
22. Diaz-Lagares C. Perez-Alvarez R. Garcia-Hernandez F. Ayala-Gutiérrez M. Callejas J. Martínez-Berriotxoa A. et al (2011) Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther 13: R112.
23. Diaz-Lagares C. Croca S. Sangle S. Vital E. Catapano F. Martínez-Berriotxoa A. et al (2012) Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 11: 357–364.
24. Dillon S. Harder B. Lewis K. Moore M. Liu H. Bukowski T. et al (2010) B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther 12: R48.
25. Dorner T. Kaufmann J. Wegener W. Teoh N. Goldenberg D. Burmester G. et al (2006) Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8: R74.
26. Eli Lilly and Company (2014) Lilly to discontinue development of tabalumab based on efficacy results in phase 3 lupus studies. Press release, 2 October 2014. Available from: https://investor.lilly.com/releasedetail.cfm?ReleaseID=874281 (accessed 5 August 2015).
27. Finck B. Linsley P. Wofsy D. (1994) Treatment of murine lupus with CTLA4Ig. Science 265: 1225–1227.
28. Fredericks C. Kvam K. Bear J. Crabtree G. Josephson S. (2014) A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab. Lupus. 14 February 2014. [Epub ahead of print]
29. Furie R. Nicholls K. Cheng T. Houssiau F. Burgos-Vargas R. Chen S. et al (2014) Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 66: 379–389.
30. Furie R. Petri M. Zamani O. Cervera R. Wallace D. Tegzová D. et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63: 3918–3930.
31. Garcia-Hernandez F. Gonzalez-Leon R. Castillo-Palma M. Ocaña-Medina C. Sánchez-Román J. (2012) Tocilizumab for treating refractory haemolytic anaemia in a patient with systemic lupus erythematosus. Rheumatology 51: 1918–1919.
32. Ginzler E. Wax S. Rajeswaran A. Copt S. Hillson J. Ramos E. et al (2012) Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 14: R33.
33. Gross J. Johnston J. Mudri S. Enselman R. Dillon S. Madden K. et al (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404: 995–999.
34. Hainz N. Thomas S. Neubert K. Meister S. Benz K. Rauh M. et al (2012) The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F 1 mouse model by preservation of glomerular and tubulointerstitial architecture. Nephron Exp Nephrol 120: e47–e58.
35. Hooks J. Moutsopoulos H. Geis S. Stahl N. Decker J. Notkins A. (1979) Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 301: 5–8.
36. Illei G. Shirota Y. Yarboro C. Daruwalla J. Tackey E. Takada K. et al (2010) Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62: 542–552.
37. Isenberg D. Gordon C. Licu D. Copt S. Rossi C. Wofsy D. (2014) Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 20 June 2014. [Epub ahead of print]
38. Jacobi A. Goldenberg D. Hiepe F. Radbruch A. Burmester G. Dörner T. (2008) Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 67: 450–457.
39. Jones R. Tervaert J. Hauser T. Luqmani R. Morgan M. Peh C. et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363: 211–220.
40. Kalkner K. Rönnblom L. Karlsson Parra A. Bengtsson M. Olsson Y. Oberg K. (1998) Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. QJM 91: 393–399.
41. Kamata Y. Minota S. (2012) Successful treatment of massive intractable pericardial effusion in a patient with systemic lupus erythematosus with tocilizumab. BMJ Case Rep. DOI: 10.1136/bcr-2012-007834.
42. Khamashta M. Merrill J. Werth V. Furie R. Kalunian K. Illei G. et al (2014) Safety and efficacy of sifalimumab, an anti IFN-alpha monoclonal antibody, in a phase 2b study of moderate to severe systemic lupus erythematosus (SLE). Arthritis Rheum (Late Breaking Abstract) 66: L4.
43. Lee-Kirsch M. Gong M. Chowdhury D. Senenko L. Engel K. Lee Y. et al (2007) Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX 1 are associated with systemic lupus erythematosus. Nat Genet 39: 1065–1067.
44. Liang B. Gardner D. Griswold D. Bugelski P. Song X. (2006) Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 119: 296–305.
45. Linker-Israeli M. Deans R. Wallace D. Prehn J. Ozeri-Chen T. Klinenberg J. (1991) Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 147: 117–123.
46. Lu T. Ng K. Cambridge G. Leandro M. Edwards J. Ehrenstein M. et al (2009) A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 61: 482–487.
47. Makol A. Gibson L. Michet C. (2012) Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis. J Clin Rheumatol 18: 92–95.
48. Mariette X. Roux S. Zhang J. Bengoufa D. Lavie F. Zhou T. et al (2003) The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 62: 168–171.
49. McBride J. Jiang J. Abbas A. Morimoto A. Li J. Maciuca R. et al (2012) Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 64: 3666–3676.
50. Merrell M. Shulman L. (1995) Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chronic Dis 1: 12–32.
51. Merrill J. Burgos-Vargas R. Westhovens R. Houssiau F. Burgos-Vargas R. Chen S. et al (2010 a) The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62: 3077–3087.
52. Merrill J. Neuwelt C. Wallace D. Shanahan J. Latinis K. Oates J. et al (2010 b) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62: 222–233.
53. Merrill J. Wallace D. Petri M. Kirou K. Yao Y. White W. et al (2011) Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 70: 1905–1913.
54. Mihara M. Takagi N. Takeda Y. Ohsugi Y. (1998) IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F 1 mice. Clin Exp Immunol 112: 397–402.
55. Moore P. Belvedere O. Orr A. Pieri K. LaFleur D. Feng P. et al (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285: 260–263.
56. Morehouse C. Chang L. Wang L. Brohawn P. Ueda S. Illei G. et al (2014) Target modulation of a type i interferon (IFN) gene signature with sifalimumab or anifrolumab in systemic lupus erythematosus (SLE) patients in two open label phase 2 Japanese trials. Arthritis Rheum 66: 719.
57. Moroni G. Quaglini S. Maccario M. Banfi G. Ponticelli C. (1996) “Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 50: 2047–2053.
58. Mosca M. Bencivelli W. Neri R. Pasquariello A. Batini V. Puccini R. et al (2002) Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int 61: 1502–1509.
59. Navarra S. Guzman R. Gallacher A. Hall S. Levy R. Jimenez R. et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377: 721–731.
60. Peng L. Oganesyan V. Wu H. Dall'Acqua W. Damschroder M. (2015) Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody. MAbs 7: 428–439.
61. Pepper R. Griffith M. Kirwan C. Levy J. Taube D. Pusey C. et al (2009) Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 24: 3717–3723.
62. Peterson E. Robertson A. Emlen W. (1996) Serum and urinary interleukin-6 in systemic lupus erythematosus. Lupus 5: 571–575.
63. Petri M. Stohl W. Chatham W. McCune W. Chevrier M. Ryel J. et al (2008) Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 58: 2453–2459.
64. Petri M. Wallace D. Spindler A. Chindalore V. Kalunian K. Mysler E. et al (2013) Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 65: 1011–1021.
65. Quartuccio L. Rupolo M. Michieli M. de Vita S. (2014) Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus. Rheumatology 53: 381–382.
66. Reiser H. Stadecker M. (1996) Costimulatory B 7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 335: 1369–1377.
67. Rice G. del Toro Duany Y. Jenkinson E. Forte G. Anderson B. Ariaudo G. et al (2014) Gain-of-function mutations in IFIH 1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat Genet 46: 503–509.
68. Rice G. Forte G. Szynkiewicz M. Chase D. Aeby A. Abdel-Hamid M. et al (2013) Assessment of interferon-related biomarkers in Aicardi-Goutieres syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol 12: 1159–1169.
69. Ronnblom L. Alm G. Oberg K. (1990) Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 227: 207–210.
70. Ronnblom L. Alm G. Oberg K. (1991) Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 115: 178–183.
71. Rossi E. Chang C. Goldenberg D. (2014) Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus. PloS ONE 9: e98315.
72. Rossi E. Goldenberg D. Michel R. Rossi D. Wallace D. Chang C. (2013) Trogocytosis of multiple B-cell surface markers by CD 22 targeting with epratuzumab. Blood 122: 3020–3029.
73. Rovin B. Furie R. Latinis K. Looney R. Fervenza F. Sanchez-Guerrero J. et al (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64: 1215–1226.
74. Ryffel B. Car B. Gunn H. Roman D. Hiestand P. Mihatsch M. (1994) Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Am J Pathol 144: 927–937.
75. Scheipers P. Reiser H. (1998) Role of the CTLA-4 receptor in T cell activation and immunity. Physiologic function of the CTLA-4 receptor. Immunol Res 18: 103–115.
76. Schneider P. Mackay F. Steiner V. Hofmann K. Bodmer J. Holler N. et al (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189: 1747–1756.
77. Shirota Y. Yarboro C. Fischer R. Pham T. Lipsky P. Illei G. (2013) Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis 72: 118–128.
78. Stohl W. (2010) Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes). Arthritis Res Ther 12: 111.
79. Stone J. Merkel P. Spiera R. Seo P. Langford C. Hoffman G. et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363: 221–232.
80. Terrier B. Amoura Z. Ravaud P. Hachulla E. Jouenne R. Combe B. et al (2010) Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 62: 2458–2466.
81. Thompson J. Bixler S. Qian F. Vora K. Scott M. Cachero T. et al (2001) BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293: 2108–2111.
82. Tsai C. Wu T. Yu C. Lu J. Tsai Y. (2000) Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 85: 207–214.
83. van Vollenhoven R. Mosca M. Bertsias G. Isenberg D. Kuhn A. Lerstrøm K. et al (2014) Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 73: 958–967.
84. van Vollenhoven R. Petri M. Cervera R. Roth D. Ji B. Kleoudis C. et al (2012) Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 7: 1343–1349.
85. Wallace D. Gordon C. Strand V. Hobbs K. Petri M. Kalunian K. et al (2013) Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology 52: 1313–1322.
86. Wallace D. Kalunian K. Petri M. Strand V. Houssiau F. Pike M. et al (2014 a) Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 73: 183–190.
87. Wallace D. Popa S. Spindler A. (2014 b) Improvement of disease activity and reduction of severe flares following subcutaneous administration of an IL-6 monoclonal antibody (mAb) in subjects with active generalized systemic lupus erythematosus (SLE). ACR abstract.
88. Wang Y. Zhou W. Zhang Z. (2015) Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient. Rheumatology 54: 194–195.
89. Wofsy D. Hillson P. Diamond B. (2013) Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum 65: 1586–1591.
90. Yang G. Liu H. Jiang M. Jiang X. Li S. Yuan Y. et al (1998) Experimental study on intramuscular injection of eukaryotic expression vector pcDNA3- IL-6 on BXSB mice. Chin Med J (Engl) 111: 38–42.
91. Ytterberg S. Schnitzer T. (1982) Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 25: 401–406.
92. Zimmer R. Scherbarth H. Rillo O. Gomez-Reino J. Muller S. (2013) Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis 72: 1830–1835.